A Food Effect Study of Apatinib Mesylate in Healthy Subjects

NCT04341090 | Completed Phase 1

• 1 other identifier: HR-APTN-I-009
• Study Type: interventional
• Target: 42
• Locations: 1 country
• Sites: 1

Brief Summary

The primary objective of the study was to assess the effect of high-fat and low-fat meal on the pharmacokinetics of apatinib mesylate in Chinese adult healthy subjects. The secondary objective of the study was to assess the safety of apatinib mesylate administered in adult healthy subjects.

Conditions

Healthy Subjects

Outcome Measures

Primary Outcomes (3)

• Cmax

  Maximum Observed Plasma Concentration for apatinib \[ Time Frame: Day 1: 0-72 hours; Day5: 0-72 hours;Day9:0-72hours \]

  Time Frame: Day 1: 0-72 hours; Day5: 0-72 hours;Day9:0-72hours

• AUC0-t

  Area Under the Concentration-time Curve From Zero (Pre-dose) to Time of Last Quantifiable Concentration for apatinib

  Time Frame: Day 1: 0-72 hours; Day5: 0-72 hours;Day9:0-72hours

• AUC0-inf

  Area Under the Plasma Concentration-time Curve from Time 0 to Infinite Time for apatinib

  Time Frame: Day 1: 0-72 hours; Day5: 0-72 hours;Day9:0-72hours

Study Arms (6)

Arm 1

EXPERIMENTAL

Drug:apatinib mesylate tablet , 250 mg, 3 discrete single doses separated by 4-days: the first dose will be after fasted, the second dose will be after low-fat meal, the third dose will be after high-fat meal

Drug: Apatinib Mesylate

Arm 2

EXPERIMENTAL

Drug:apatinib mesylate tablet , 250 mg, 3 discrete single doses separated by 4-days: the first dose will be after high-fat meal, the second dose will be after fasted, the third dose will be after low-fat meal

Drug: Apatinib Mesylate

Arm 3

EXPERIMENTAL

Drug:apatinib mesylate tablet , 250 mg, 3 discrete single doses separated by 4-days: the first dose will be after low-fat meal, the second dose will be after high-fat meal, the third dose will be after fasted

Drug: Apatinib Mesylate

Arm 4

EXPERIMENTAL

Drug:apatinib mesylate tablet , 250 mg, 3 discrete single doses separated by 4-days: the first dose will be after fasted, the second dose will be after high-fat meal, the third dose will be after low-fat meal

Drug: Apatinib Mesylate

Arm 5

EXPERIMENTAL

Drug:apatinib mesylate tablet , 250 mg, 3 discrete single doses separated by 4-days: the first dose will be after low-fat meal, the second dose will be after fasted, the third dose will be after high-fat meal

Drug: Apatinib Mesylate

Arm 6

EXPERIMENTAL

Drug:apatinib mesylate tablet , 250 mg, 3 discrete single doses separated by 4-days: the first dose will be after high-fat meal, the second dose will be after low-fat meal, the third dose will be after fasted

Drug: Apatinib Mesylate

Interventions

Apatinib Mesylate DRUG

Single dose of apatinib mesylate after high-fat meal, low fat meal and fast

Arm 1; Arm 2; Arm 3; Arm 4; Arm 5; Arm 6

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• years of age, male or female, each gender should be more than 1/4 of the whole sample size.
• The weight of male subject ≥50kg, weight of female subject ≥45kg, 19≤BMI≤28kg/m2
• In good health, determined by no clinically significant findings from medical history, physical examination, 12-lead ECG;
• Agree to take approved method of contraception during the clinical trail and 8 weeks after the last dose of apatinib. Female subject should be negative in the pregnancy test;
• Able to comprehend and willing to sign an informed consent form (ICF)

You may not qualify if:

• History of drug allergy, or allergic to apatinib or ingredients;
• Drinking 14 units of alcohol per week within 6 months prior dosing(1 unit = 360 mL of beer, or 150mL of wine) ;
• Take any prescription or traditional Chinese medicines within four weeks prior dosing; take any over-the-counter medication, vitamin products within two weeks before dosing;
• Take any clinical trial drugs within 3 months prior dosing;
• Participate in blood donation within 3 months before screening and donate blood volume ≥400mL or blood loss ≥400mL, or receive blood transfusion; or donate blood volume≥200mL or blood loss ≥200mL within 1 month prior dosing.
• Combined with other viral infections (anti-HCV, anti-HIV positive, HBsAg positive) or combined with syphilis infection;
• Anyone who refuse to stop ingest foods or drinks containing caffeine, xanthine or alcohol from 48 hours before dosing to the end of the study;
• Anyone who refuse to stop ingesting grapefruit or grapefruit-containing products from 7 days before dosing to the end of the study;
• The investigator believes that the subjects are not eligible to participate in this trial.

Sponsors & Collaborators

• Jiangsu HengRui Medicine Co., Ltd.: lead

Study Sites (1)

Beijing Luhe Hospital, Capital Medical University

Beijing, Beijing Municipality, 101100, China

Location

MeSH Terms

Interventions

apatinib

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: OTHER
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 8, 2020
• First Posted: April 10, 2020
• Study Start: May 13, 2020
• Primary Completion: July 6, 2020
• Study Completion: July 6, 2020
• Last Updated: October 22, 2021

Record last verified: 2021-10

Locations

CN (1)